
Quarterly ResultJul 29, 2026, 06:36 AM
Boston Scientific Q2 Net Sales $5.44B, Adj. EPS $0.86
AI Summary
Boston Scientific Corporation announced strong second-quarter 2026 financial results, with net sales reaching $5.442 billion, a 7.5% increase on a reported basis. The company reported adjusted EPS of $0.86, surpassing its guidance range. Key developments include the completion of a $2 billion accelerated share repurchase program and a $1.5 billion investment in MiRus LLC. Boston Scientific also provided updated full-year 2026 guidance, projecting net sales growth of 5.5% to 6.5% and adjusted EPS of $3.28 to $3.32.
Key Highlights
- Q2 2026 net sales reached $5.442 billion, up 7.5% reported and 7.0% operational/organic.
- Q2 2026 GAAP EPS was $0.61, and adjusted EPS was $0.86, exceeding guidance of $0.82-$0.84.
- MedSurg segment net sales grew 5.9% reported and 5.4% operational/organic.
- Cardiovascular segment net sales grew 8.3% reported and 7.8% operational/organic.
- Completed a $2 billion accelerated share repurchase program, repurchasing approximately 40 million shares.
- Invested $1.5 billion in MiRus LLC for an approximate 34% equity stake and an option to acquire its TAVR business.
- Full-year 2026 net sales guidance is 5.5% to 6.5% reported and 5% to 6% organic.
- Full-year 2026 adjusted EPS guidance is $3.28 to $3.32.
Price Impact
More from BSX